RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer

Oncogene

Volumn 35, Issue 20, 2016, Pages 2664-2674

  Qiao, Y ^a   Lin, S J ^b   Chen, Y ^a   Voon, D C C ^a   Zhu, F ^c   Chuang, L S H ^a   Wang, T ^a   Tan, P ^a,b,d,e   Lee, S C ^a,c   Yeoh, K G ^f   Sudol, M ^f,g,h   Ito, Y ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; TRANSCRIPTION FACTOR RUNX3; DNA; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; STOMACH CANCER; STOMACH EPITHELIUM; TUMOR SUPPRESSOR GENE; ALPHA HELIX; AMINO ACID SEQUENCE; CARCINOGENESIS; CHEMISTRY; EPITHELIUM CELL; GENETICS; METABOLISM; MUTATION; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CARCINOGENESIS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA; EPITHELIAL CELLS; HUMANS; MUTATION; PROTEIN CONFORMATION, ALPHA-HELICAL; PROTEIN DOMAINS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84941710782     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.338     Document Type: Article

References (59)

1. Shah MA, Ajani JA. Gastric cancer-an enigmatic and heterogeneous disease. JAMA 2010; 303: 1753-1754.
2. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124.
3. Fan XY, Hu XL, Han TM, Wang NN, Zhu YM, Hu W et al. Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis. BMC Gastroenterol 2011; 11: 92.
4. Ito Y, Bae SC, Chuang LS. The RUNX family: developmental regulators in cancer. Nat Rev Cancer 2015; 15: 81-95.
5. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 2005; 25: 8097-8107.
6. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 2006; 26: 4474-4488.
7. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008; 14: 226-237.
8. Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH et al. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 2013; 24: 603-616.
9. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994; 9: 2145-2152.
10. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562.
11. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005; 122: 421-434.
12. Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA et al. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis 2013; 35: 1020-1027.
13. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
14. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15: 1229-1241.
15. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 158: 171-184.
16. Li H, Wang Z, Zhang W, Qian K, Liao G, Xu W et al. VGLL4 inhibits EMT in part through suppressing Wnt/beta-catenin signaling pathway in gastric cancer. Med Oncol 2015; 32: 83.
17. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133.
18. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
19. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012; 11: 1090-1096.
20. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71: 2728-2738.
21. Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS et al. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer 2011; 10: 122.
22. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005; 11: 5809-5820.
23. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014; 25: 166-180.
24. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92: 7819-7823.
25. Bork P, Sudol M. The WW domain: a signalling site in dystrophin? Trends Biochem Sci 1994; 19: 531-533.
26. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23: 790-799.
27. Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell Jr AD, Sudol M et al. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumosphere formation in breast cancer cells. Oncotarget 2015 (in press).
28. Anbanandam A, Albarado DC, Nguyen CT, Halder G, Gao X, Veeraraghavan S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. Proc Natl Acad Sci USA 2006; 103: 17225-17230.
29. Koh CP, Wang CQ, Ng CE, Ito Y, Araki M, Tergaonkar V et al. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes. Leukemia 2013; 27: 1793-1802.
30. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
31. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474: 179-183.
32. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 2009; 5: e1000676.
33. Lin YT, Ding JY, Li MY, Yeh TS, Wang TW, Yu JY. YAP regulates neuronal differentiation through Sonic hedgehog signaling pathway. Exp Cell Res 2012; 318: 1877-1888.
34. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2012; 31: 527-534.
35. Voon DC, Wang H, Koo JK, Nguyen TA, Hor YT, Chu YS et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells 2012; 30: 2088-2099.
36. Yamada C, Ozaki T,o K, Suenaga Y, Inoue K, Ito Y et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010; 285: 16693-16703.
37. Wang CQ, Krishnan V, Tay LS, Chin DW, Koh CP, Chooi JY et al. Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. Cell Rep 2014; 8: 767-782.
38. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014; 158: 157-170.
39. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 2010; 19: 831-844.
40. Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012; 3: 267-285.
41. Chakraborty PK, Zhang Y, Coomes AS, Kim WJ, Stupay R, Lynch LD et al. G proteincoupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. Cancer Res 2014; 74: 3489-3500.
42. Fukumoto Y, Kurita S, Takai Y, Ogita H. Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein. J Biol Chem 2011; 286: 43537-43548.
43. Li P, Lin Y, Zhang Y, Zhu Z, Huo K. SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. J Transl Med 2013; 11: 52.
44. Rho SB, Byun HJ, Park SY, Chun T. Calpain 6 supports tumorigenesis by inhibiting apoptosis and facilitating angiogenesis. Cancer Lett 2008; 271: 306-313.
45. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25: 51-63.
46. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathwayindependent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286: 7018-7026.
47. Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012; 31: 128-134.
48. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res 2014; 24: 331-343.
49. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
50. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441-E2450.
51. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-574.
52. Tsutsumi R, Masoudi M, Takahashi A, Fujii Y, Hayashi T, Kikuchi I et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev Cell 2013; 26: 658-665.
53. Lochhead P, El-Omar EM. Gastric cancer. Br Med Bull 2008; 85: 87-100.
54. Tsang YH, Lamb A, Romero-Gallo J, Huang B, Ito K, Peek Jr RM et al. Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. Oncogene 2010; 29: 5643-5650.
55. Cinghu S, Goh YM, Oh BC, Lee YS, Lee OJ, Devaraj H et al. Phosphorylation of the gastric tumor suppressor RUNX3 following H. pylori infection results in its localization to the cytoplasm. J Cell Physiol 2012; 227: 1071-1080.
56. Min B, Kim MK, Zhang JW, Kim J, Chung KC, Oh BC et al. Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol 2012; 227: 839-849.
57. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ,ers RA et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-1305.
58. Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X et al. SMARCA3, a chromatinremodeling factor, is required for p11-dependent antidepressant action. Cell 2013; 152: 831-843.
59. Dembele D, Kastner P. Fold change rank ordering statistics: a new method for detecting differentially expressed genes. BMC Bioinformatics 2014; 15: 14.